Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$44.80 -0.1%	$37.11	$21.72 ▼ $45.48	$8.51B	1.11	3.06 million shs	567,103 shs
GMTX Gemini Therapeutics	$54.50 +0.7%	$48.22	$1.16 ▼ $14.10	$2.36B	-0.12	189,291 shs	1.06 million shs
LNTH Lantheus	$81.65 +1.1%	$84.72	$73.11 ▼ $126.89	$5.61B	0.11	1.01 million shs	1.39 million shs
RVMD Revolution Medicines	$37.25 +0.9%	$39.61	$29.17 ▼ $89.98	$7.02B	1.1	1.65 million shs	122 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	0.00%	+7.50%	+30.44%	+29.77%	+77.10%
GMTX Gemini Therapeutics	0.00%	+5.60%	+16.28%	+4.09%	+20.92%
LNTH Lantheus	0.00%	+2.90%	+7.92%	-16.51%	+1.49%
RVMD Revolution Medicines	0.00%	-6.93%	-7.68%	+4.38%	-4.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6864 of 5 stars	4.5	2.0	0.0	3.9	2.7	3.3	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	4.3621 of 5 stars	3.5	1.0	0.0	4.2	1.9	2.5	1.9
RVMD Revolution Medicines	4.5174 of 5 stars	4.5	2.0	0.0	4.7	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.42	28.16% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
LNTH Lantheus	3.00	Buy	$130.50	59.84% Upside
RVMD Revolution Medicines	3.00	Buy	$67.58	81.44% Upside

Current Analyst Ratings Breakdown

Latest GMTX, RVMD, LNTH, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/25/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/24/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00 ➝ $73.00
6/24/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	38.34	N/A	N/A	($7.71) per share	-5.81
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
LNTH Lantheus	$1.53B	3.68	$7.11 per share	11.49	$15.65 per share	5.22
RVMD Revolution Medicines	$11.58M	599.15	N/A	N/A	$13.47 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
LNTH Lantheus	$312.44M	$3.52	23.05	12.94	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)

Latest GMTX, RVMD, LNTH, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
GMTX Gemini Therapeutics	N/A	71.49	71.49
LNTH Lantheus	0.49	5.74	5.46
RVMD Revolution Medicines	N/A	13.46	13.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
GMTX Gemini Therapeutics	75.42%
LNTH Lantheus	99.06%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
GMTX Gemini Therapeutics	12.90%
LNTH Lantheus	2.00%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable

GMTX, RVMD, LNTH, and BBIO Headlines

Recent News About These Companies

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

2 hours ago | globenewswire.com

Lunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 29 at 7:38 AM | marketbeat.com

Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Target Price at $67.58

June 29 at 2:17 AM | americanbankingnews.com

Q3 EPS Estimate for Revolution Medicines Raised by Analyst

June 27 at 6:19 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Guggenheim

June 26, 2025 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Needham & Company LLC

June 26, 2025 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Given Outperform Rating at Wedbush

June 26, 2025 | americanbankingnews.com

Revolution Medicines' (RVMD) Buy Rating Reiterated at Guggenheim

June 25, 2025 | marketbeat.com

Wedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | Nasdaq

June 24, 2025 | nasdaq.com

Needham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What Happened

June 24, 2025 | marketbeat.com

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

June 24, 2025 | reuters.com

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

June 24, 2025 | globenewswire.com

Revolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...

June 23, 2025 | finanznachrichten.de

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 23, 2025 | globenewswire.com

SG Americas Securities LLC Acquires 15,164 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

June 22, 2025 | marketbeat.com

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

June 19, 2025 | seekingalpha.com

GAMMA Investing LLC Purchases 20,696 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

June 18, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX, RVMD, LNTH, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$44.80 -0.06 (-0.13%)

As of 09:37 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Gemini Therapeutics NASDAQ:GMTX

$54.50 +0.37 (+0.68%)

As of 06/27/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Lantheus NASDAQ:LNTH

$81.65 +0.91 (+1.12%)

As of 09:37 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Revolution Medicines NASDAQ:RVMD

$37.25 +0.34 (+0.92%)

As of 09:37 AM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time